Farhad Jadidi-Niaragh
Overview
Explore the profile of Farhad Jadidi-Niaragh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
3878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robat-Jazi B, Mahalleh M, Dashti M, Nejati N, Ahmadpour M, Alinejad E, et al.
Anticancer Agents Med Chem
. 2025 Feb;
PMID: 39901537
Background: Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common, with low overall survival rates. G protein-coupled receptor, class C, group...
2.
Kalaei Z, Shekarchi A, Hojjat-Farsangi M, Jalali P, Jadidi-Niaragh F
Mol Biol Rep
. 2024 Sep;
51(1):1027.
PMID: 39347868
Several cells and molecules in the tumor microenvironment have been introduced as effective factors in the prognosis and progression of colorectal cancer. As a key element of the intermediate filament...
3.
Bakhshivand M, Masoumi J, Ghorbaninezhad F, Aghebati-Maleki L, Shanebandi D, Sandoghchian Shotorbani S, et al.
Heliyon
. 2024 Sep;
10(18):e37699.
PMID: 39309891
Anticancer immunotherapies with a dendritic Cell (DC) basis are becoming more popular. However, it has been suggested that the tumor's immunosuppressive mechanisms, such as inhibitory immunological checkpoint molecules, reduce the...
4.
Fathi M, Zarei A, Moghimi A, Jalali P, Salehi Z, Gholamin S, et al.
Expert Opin Ther Targets
. 2024 Sep;
28(9):757-777.
PMID: 39305018
Introduction: Cancer immunotherapy has revolutionized the field of oncology, offering new hope to patients with advanced malignancies. Tumor-induced immunosuppression limits the effectiveness of current immunotherapeutic strategies, such as PD-1/PDL-1 checkpoint...
5.
Fathi M, Bahmanpour S, Barshidi A, Rasouli H, Kiani F, Khesht A, et al.
Int Immunopharmacol
. 2024 Sep;
142(Pt A):113118.
PMID: 39271379
No abstract available.
6.
Dashti M, Datshi M, Habibi M, Nejati N, Robat-Jazi B, Ahmadpour M, et al.
Anticancer Agents Med Chem
. 2024 Aug;
25(1):42-51.
PMID: 39192642
Objectives: Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell...
7.
Khesht A, Karpisheh V, Saeed B, Zekiy A, Yapanto L, Nabi Afjadi M, et al.
Int Immunopharmacol
. 2024 Jul;
138:112594.
PMID: 39075740
No abstract available.
8.
Sadeghi M, Moslehi A, Kheiry H, Kiani F, Zarei A, Khodakarami A, et al.
Cancer Cell Int
. 2024 Jun;
24(1):217.
PMID: 38918761
Background: Acute myeloid leukemia (AML), a malignancy Often resistant to common chemotherapy regimens (Cytarabine (Ara-c) + Daunorubicin (DNR)), is accompanied by frequent relapses. Many factors are involved in causing chemoresistance....
9.
Kiani F, Izadi S, Dezfouli E, Ebrahimi F, Mohammadi M, Chalajour H, et al.
Life Sci
. 2024 Jun;
350:122775.
PMID: 38851943
No abstract available.
10.
Hashemi V, Ahmadi A, Malakotikhah F, Chaleshtari M, Moornani M, Masjedi A, et al.
Life Sci
. 2024 Jun;
350:122772.
PMID: 38845264
No abstract available.